Danaher has been in China for 15 years and continues to increase its size in China's large market

• Beckman Coulter builds an ecosystem of local strategic partners

As one of the first IVD companies to build a factory in China, Beckman Coulter has a history of local production for 25 years since the establishment of a factory in Suzhou in 1997
.
Beckman Coulter actively deploys to build a Chinese R&D team, makes use of local superior resources, quickly launches high-quality instruments and reagents to meet the needs of Chinese customers, not only serves the Chinese market, but also supplies products to the global market
.
At present, Beckman Coulter has successfully transferred many product lines from Europe, the United States, Japan and other products to Suzhou, China to achieve local production
.
The DxA 5000 conversion project of Beckman Coulter's smart laboratory automation solution is progressing smoothly, becoming its first large-scale instrument
to achieve localized production in China.

Xiaosui Chen, global vice president and general manager of Beckman Coulter China, said: "Beckman is the first foreign-funded IVD company to enter China and the first IVD company
to establish a factory in China.
This year marks the 25th anniversary
of Beckman Coulter's local plant.
At the same time, Beckman Coulter has been actively cooperating with outstanding local enterprises to build a strategic partner ecosystem
.
This year, we launched the localized brand 'Bei Huakang' with the meaning of 'committed to Chinese health', and cooperated with many high-quality local IVD enterprises to jointly develop excellent, intelligent and comprehensive diagnostic products and smart laboratory solutions, close to the needs of the local market and serve Chinese customers
.
" "

• Leica Biosystems builds high-level Chinese factories

There are about 4 million malignant tumors in China every year, and pathological diagnosis is the gold standard
for cancer diagnosis.
In recent years, China has actively promoted the sinking of medical resources and the construction of hierarchical diagnosis and treatment to ensure the diagnosis and treatment
of grassroots patients.
Guohong, General Manager of Leica Biosystems China, said: "In its 150-year history, Leica Biosystems has been constantly innovating for pathological diagnosis, and it is the only company
with a full process from biopsy to diagnosis.
In the process of localization, we still maintain an excellent level of production
.
From 2018 to 2022, our China facility was selected from hundreds of Danaher facilities worldwide and was awarded Danaher World's Best Factory for four consecutive years
.
We will continue to promote the construction of grassroots pathology departments and provide assistance
for the diagnosis and treatment of primary cancer patients.
"

In 2022, under the layout of Danaher's "Intron China" localization strategy, the Leica plant will increase investment in local R&D and production, aiming to achieve a locally developed and produced product
at every step in the whole process of pathology in the future.
The expansion project has entered the site selection stage
.

Fang Guohong also introduced the world's premiere Leica Apex CT 6 digital slide scanner, which not only has the ability to independently process different colors, but also provides advanced digital means and overall solutions such as digital imaging, remote diagnosis, and AI analysis, which can enable the pathology department to provide results faster and more accurately, and help promote the construction of pathology specialty centers and graded diagnosis and treatment
.

• Leica Microsystems builds local R&D, manufacturing and service capabilities

Chen Huai, General Manager of Leica Microsystems China, recalled Leica Microsystems' local journey in China for more than 30 years: "As early as 1985, Leica Microsystems set up a company in Hong Kong to enter the Chinese market, followed by a factory and R&D center
.
In 2019, we established a R&D center in Suzhou to use China's innovation capabilities to design advanced digital microscopes
that can be applied in the Chinese market and in the global market.
In 2021, Leica China's first customer experience center opened
.
In September 2022, the first batch of nationally produced MIC W10 series microscopes was officially delivered, marking that Leica has achieved full capacity
in China's R&D and production.
"

Leica Microsystems' world's first full-scene microscopy imaging analysis platform MICA, was also officially unveiled at the Expo
.
MICA eliminates more than 60% of the steps, shortens the training time for scientists by 50%, and can quickly get started with high-precision results
.

• Cytiva increased its capital by 60 million yuan to upgrade the China Science and Technology Innovation Center to help the development of China's biopharmaceutical industry

Finally, Yu Lihua, General Manager of Cytiva China, announced that she will increase its capital of 60 million RMB to build a China Science and Technology Innovation Center in China to provide upstream and downstream products, technologies, services and innovative solutions
for the biopharmaceutical industry in terms of bioprocess R&D and clinical production, new therapy incubation, talent training, intelligent manufacturing and services, and regulatory verification.
After the capital increase, the total investment of Cytiva China Science and Technology Innovation Center is nearly 100 million yuan
.

China's biopharmaceuticals are in a stage
of rapid development.
This year, the National Development and Reform Commission issued the 14th Five-Year Plan for the Development of the Bio-economy for the first time, which has brought the innovation and development of the biopharmaceutical industry to a new height
.
Yu Lihua said: "Cytiva has witnessed the vigorous development of China's biopharmaceutical industry and is very honored to be an accelerator
to promote industrial innovation.
We will continue to bring the world's cutting-edge technology, hardware and services to the domestic market, and at the same time continue to expand cooperation with local enterprises, governments and research institutions to jointly build an industry development ecology and help China's biopharmaceutical industry become bigger and stronger
.
"

Zhang Lei, General Manager of Customer Service of Cytiva China, also released the world's first OptiRun^TM digital remote service center, which uses augmented reality and Internet of Things technology to realize the whole process of remote intelligent services
of rapid remote response, accurate remote diagnosis, and efficient remote repair.

Cetiva also brought a number of localized new products and key products: China premiere, using Cytiva's global unified quality system standards, flexible to adapt to the customized needs of local customers disposable stirred reaction bag 50-2500L Xcellerex; Biacore^TM8K
, a new generation of high-throughput, high-data quality molecular interaction analysis system that can quickly complete the screening and quality control of small molecule compounds and biological drugs, and has obtained FDA and EMA certification, and has been indexed by the Chinese, American and Japanese pharmacopoeias.

In addition, many Danaher companies are actively seizing local opportunities and exploring new paradigms of localization
.
With the vigorous development of China's semiconductor industry, Danaher's Pall Group Microelectronics Division is accelerating China's localization layout, setting up R&D centers and technical support application centers, expanding the manufacturing capabilities of microelectronic filtration products, completing a series of manufacturing, R&D and application actions locally, and using China's supply chain and talent base to better serve customers in Asia Pacific and China
.
From 2022 to 2025, Pall will invest 70 million yuan in China to further expand the semiconductor product categories and production capacity
of the Beijing plant.

Danaher Group's world guardian of water quality, Hash, invested in Shanghai in 2002 and has since mass-produced
a new product in Hash's China plant almost every year.
The Hash China factory has hundreds of employees, dozens of key production lines, nearly 5,000 square meters of factory buildings, and the production area has been three times
larger than the original scale.
Hash continues to drive the upgrading of local supply chains and industrial chains to achieve common "innovation and intelligent manufacturing"
.
At present, the local procurement rate of locally manufactured components exceeds 85%, and it is planning to achieve localized replacement
in core chips and other fields.
At the same time, Hash China has nearly 50 local R&D personnel, specializing in serving the local market, realizing China's R&D completely independent ownership, and independently mastering a number of core technologies, such as finely controlled flow path design, colorimetric unit design, all software architecture and software modules, reagents with good measurement stability, etc
.

During the 5th CIIE, Danaher Group will also focus on the Healthy China strategy, and sign strategic cooperation with partners including China Health Media Group, Health Development Research Center of the National Health Commission, Boao Yiling Hospital Management Group, Guokang Lecheng, GE Healthcare, Chongqing Medical University, Shenzhen Third Hospital and other partners, based on the new starting point of the 15th anniversary in China, promote the upgrading of China's health industry, and work with multiple partners to accelerate the high-quality development of
the medical health and biomedical industry.